| Year |
Citation |
Score |
| 2024 |
Morales AE, Gumenick R, Genovese CM, Jang YY, Ouedraogo A, Ibáñez de Garayo M, Pannellini T, Patel S, Bott ME, Alvarez J, Mun SS, Totonchy J, Gautam A, Delgado de la Mora J, Chang S, ... ... Scheinberg DA, et al. Wilms' tumor 1 (WT1) antigen is overexpressed in Kaposi Sarcoma and is regulated by KSHV vFLIP. Plos Pathogens. 20: e1011881. PMID 38190392 DOI: 10.1371/journal.ppat.1011881 |
0.314 |
|
| 2023 |
Dao T, Xiong G, Mun SS, Meyerberg J, Korontsvit T, Xiang J, Cui Z, Chang AY, Jarvis CA, Cai W, Luo H, Pierson AJ, Daniyan AF, Yoo S, Takao S, ... ... Scheinberg DA, et al. Dual-receptor T cell platform with Ab-TCR and costimulatory receptor achieves specificity and potency against AML. Blood. PMID 38048594 DOI: 10.1182/blood.2023021054 |
0.677 |
|
| 2023 |
Kurtz K, Eibler L, Dacek MM, Carter LM, Veach DR, Lovibond S, Reynaud E, Qureshy S, McDevitt MR, Bourne C, Monette S, Punzalan B, Khayat S, Verma S, Kesner AL, ... ... Scheinberg DA, et al. Engineering CAR-T cells for radiohapten capture in imaging and radioimmunotherapy applications. Theranostics. 13: 5469-5482. PMID 37908719 DOI: 10.7150/thno.87489 |
0.306 |
|
| 2023 |
Molvi Z, Klatt MG, Dao T, Urraca J, Scheinberg DA, O'Reilly RJ. The landscape of MHC-presented phosphopeptides yields actionable shared tumor antigens for cancer immunotherapy across multiple HLA alleles. Journal For Immunotherapy of Cancer. 11. PMID 37775115 DOI: 10.1136/jitc-2023-006889 |
0.492 |
|
| 2023 |
Mun SS, Meyerberg J, Peraro L, Korontsvit T, Gardner T, Malviya M, Kyi C, O'Cearbhaill RE, Liu C, Dao T, Scheinberg DA. Dual targeting ovarian cancer by Muc16 CAR T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1. Cancer Immunology, Immunotherapy : Cii. PMID 37635172 DOI: 10.1007/s00262-023-03529-w |
0.374 |
|
| 2023 |
Malviya M, Aretz ZEH, Molvi Z, Lee J, Pierre S, Wallisch P, Dao T, Scheinberg DA. Challenges and solutions for therapeutic TCR-based agents. Immunological Reviews. PMID 37455333 DOI: 10.1111/imr.13233 |
0.338 |
|
| 2023 |
Bourne CM, Wallisch P, Dacek MM, Gardner TJ, Pierre S, Vogt K, Corless BC, Bah MA, Romero-Pichardo JE, Charles A, Kurtz KG, Tan DS, Scheinberg DA. Host Interactions with Engineered T-cell Micropharmacies. Cancer Immunology Research. PMID 37379366 DOI: 10.1158/2326-6066.CIR-22-0879 |
0.315 |
|
| 2023 |
Mun SS, Peraro L, Meyerberg J, Korontsvit T, Malviya M, Gardner T, Kyi C, O'Cearbhaill RE, Liu C, Dao T, Scheinberg DA. Dual targeting ovarian cancer by Muc16 CAR-T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1. Research Square. PMID 37214945 DOI: 10.21203/rs.3.rs-2887299/v1 |
0.374 |
|
| 2023 |
Bourne CM, Wallisch P, Dacek M, Gardner T, Pierre S, Vogt K, Corless BC, Bah MA, Pichardo JR, Charles A, Kurtz KG, Tan DS, Scheinberg DA. Host-cell Interactions of Engineered T cell Micropharmacies. Biorxiv : the Preprint Server For Biology. PMID 37205431 DOI: 10.1101/2023.04.05.535717 |
0.316 |
|
| 2023 |
Molvi Z, Klatt MG, Dao T, Urraca J, Scheinberg DA, O'Reilly RJ. The landscape of MHC-presented phosphopeptides yields actionable shared tumor antigens for cancer immunotherapy across multiple HLA alleles. Biorxiv : the Preprint Server For Biology. PMID 36798179 DOI: 10.1101/2023.02.08.527552 |
0.502 |
|
| 2023 |
Dacek MM, Kurtz K, Wallisch P, Pierre SA, Khayat SS, Bourne CM, Gardner TJ, Vogt KC, Aquino N, Younes A, Scheinberg DA. Potentiating antibody-dependent killing of cancers with CAR T cells secreting CD47-SIRPα checkpoint blocker. Blood. PMID 36696633 DOI: 10.1182/blood.2022016101 |
0.335 |
|
| 2022 |
Kirkey DC, Loeb A, Castro S, McKay CN, Perkins L, Pardo L, Leonti AR, Tang T, Loken MR, Eidenschink Brodersen L, Loeb KR, Scheinberg DA, Le Q, Meshinchi S. Therapeutic targeting PRAME with mTCRCAR T cells in acute myeloid leukemia. Blood Advances. PMID 35984639 DOI: 10.1182/bloodadvances.2022008304 |
0.378 |
|
| 2022 |
Bourne CM, Mun SS, Dao T, Aretz ZEH, Molvi Z, Gejman RS, Daman A, Takata K, Steidl C, Klatt MG, Scheinberg DA. Unmasking the suppressed immunopeptidome of EZH2 mutated diffuse large B-cell lymphomas with combination drug treatment. Blood Advances. PMID 35561310 DOI: 10.1182/bloodadvances.2021006069 |
0.775 |
|
| 2022 |
Chandran SS, Ma J, Klatt MG, Dündar F, Bandlamudi C, Razavi P, Wen HY, Weigelt B, Zumbo P, Fu SN, Banks LB, Yi F, Vercher E, Etxeberria I, Bestman WD, ... ... Scheinberg DA, et al. Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA. Nature Medicine. PMID 35484264 DOI: 10.1038/s41591-022-01786-3 |
0.335 |
|
| 2022 |
Klatt MG, Dao T, Yang Z, Liu J, Mun SS, Dacek MM, Luo H, Gardner TJ, Bourne CM, Peraro L, Aretz ZEH, Korontsvit T, Lau M, Kharas MG, Liu C, ... Scheinberg DA, et al. A TCR Mimic CAR T Cell Specific for NDC80 Is Broadly Reactive With Solid Tumors and Hematological Malignancies. Blood. PMID 35427421 DOI: 10.1182/blood.2021012882 |
0.394 |
|
| 2022 |
Takata K, Chong LC, Ennishi D, Aoki T, Li MY, Thakur A, Healy S, Viganò E, Dao T, Kwon D, Duns G, Nielsen JS, Ben-Neriah S, Tse E, Hung SS, ... ... Scheinberg DA, et al. Tumor associated antigen PRAME exhibits dualistic functions that are targetable in diffuse large B-cell lymphoma. The Journal of Clinical Investigation. PMID 35380993 DOI: 10.1172/JCI145343 |
0.315 |
|
| 2022 |
Dao T, Mun SS, Molvi Z, Korontsvit T, Klatt MG, Khan AG, Nyakatura EK, Pohl MA, White TE, Balderes PJ, Lorenz IC, O'Reilly RJ, Scheinberg DA. A TCR mimic monoclonal antibody reactive with the "public" phospho-neoantigen pIRS2/HLA-A*02:01 complex. Jci Insight. 7. PMID 35260532 DOI: 10.1172/jci.insight.151624 |
0.547 |
|
| 2021 |
Gardner TJ, Lee JP, Bourne CM, Wijewarnasuriya D, Kinarivala N, Kurtz KG, Corless BC, Dacek MM, Chang AY, Mo G, Nguyen KM, Brentjens RJ, Tan DS, Scheinberg DA. Engineering CAR-T cells to activate small-molecule drugs in situ. Nature Chemical Biology. PMID 34969970 DOI: 10.1038/s41589-021-00932-1 |
0.659 |
|
| 2021 |
Peraro L, Bourne CM, Dacek MM, Akalin E, Park JH, Smith EL, Scheinberg DA. Incorporation of bacterial immunoevasins to protect cell therapies from host antibody-mediated immune rejection. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 34217891 DOI: 10.1016/j.ymthe.2021.06.022 |
0.323 |
|
| 2021 |
Charles A, Bourne CM, Korontsvit T, Aretz ZEH, Mun SS, Dao T, Klatt MG, Scheinberg DA. Low-dose CDK4/6 inhibitors induce presentation of pathway specific MHC ligands as potential targets for cancer immunotherapy. Oncoimmunology. 10: 1916243. PMID 34104540 DOI: 10.1080/2162402X.2021.1916243 |
0.34 |
|
| 2021 |
Dacek MM, Veach DR, Cheal SM, Carter LM, McDevitt MR, Punzalan B, Burnes Vargas D, Kubik TZ, Monette S, Santich BH, Yang G, Ouerfelli O, Kesner AL, Cheung NV, Scheinberg DA, et al. Engineered Cells as a Test Platform for Radiohaptens in Pretargeted Imaging and Radioimmunotherapy Applications. Bioconjugate Chemistry. PMID 33819023 DOI: 10.1021/acs.bioconjchem.0c00595 |
0.3 |
|
| 2021 |
Jones HF, Molvi Z, Klatt MG, Dao T, Scheinberg DA. Empirical and Rational Design of T Cell Receptor-Based Immunotherapies. Frontiers in Immunology. 11: 585385. PMID 33569049 DOI: 10.3389/fimmu.2020.585385 |
0.332 |
|
| 2020 |
Dao T, Klatt MG, Korontsvit T, Mun SS, Guzman S, Mattar M, Zivanovic O, Kyi CK, Socci ND, O'Cearbhaill RE, Scheinberg DA. Impact of tumor heterogeneity and microenvironment in identifying neoantigens in a patient with ovarian cancer. Cancer Immunology, Immunotherapy : Cii. PMID 33123756 DOI: 10.1007/s00262-020-02764-9 |
0.335 |
|
| 2020 |
Krebs S, Dacek MM, Carter LM, Scheinberg DA, Larson SM. CAR Chase: Where Do Engineered Cells Go in Humans? Frontiers in Oncology. 10: 577773. PMID 33042849 DOI: 10.3389/Fonc.2020.577773 |
0.396 |
|
| 2020 |
Klatt MG, Mack KN, Bai Y, Aretz ZE, Nathan LI, Mun SS, Dao T, Scheinberg DA. Solving an MHC allele specific bias in the reported immunopeptidome. Jci Insight. PMID 32897882 DOI: 10.1172/Jci.Insight.141264 |
0.377 |
|
| 2020 |
Gardner TJ, Bourne CM, Dacek MM, Kurtz K, Malviya M, Peraro L, Silberman PC, Vogt KC, Unti MJ, Brentjens R, Scheinberg D. Targeted Cellular Micropharmacies: Cells Engineered for Localized Drug Delivery. Cancers. 12. PMID 32764348 DOI: 10.3390/Cancers12082175 |
0.444 |
|
| 2020 |
Klatt MG, Aretz ZEH, Curcio M, Gejman RS, Jones HF, Scheinberg DA. An input-controlled model system for identification of MHC bound peptides enabling laboratory comparisons of immunopeptidome experiments. Journal of Proteomics. 103921. PMID 32758705 DOI: 10.1016/J.Jprot.2020.103921 |
0.765 |
|
| 2020 |
Gejman RS, Jones HF, Klatt MG, Chang AY, Oh CY, Chandran SS, Korontsvit T, Zakahleva V, Dao T, Klebanoff CA, Scheinberg DA. Identification of the targets of T cell receptor therapeutic agents and cells by use of a high throughput genetic platform. Cancer Immunology Research. PMID 32184297 DOI: 10.1158/2326-6066.Cir-19-0745 |
0.831 |
|
| 2020 |
Urbanska AM, Khanin R, Alidori S, Wong S, Mello BP, Almeida BA, Chen F, Ma K, Turker MZ, Korontsvit T, Scheinberg DA, Zanzonico PB, Wiesner U, Bradbury MS, Quinn TP, et al. A Genomic Profile of Local Immunity in the Melanoma Microenvironment Following Treatment with α Particle-Emitting Ultrasmall Silica Nanoparticles. Cancer Biotherapy & Radiopharmaceuticals. PMID 32013538 DOI: 10.1089/Cbr.2019.3150 |
0.393 |
|
| 2020 |
Mondello P, Tadros S, Teater M, Fontan L, Chang AY, Jain N, Yang H, Singh S, Ying HY, Chu CS, Ma MCJ, Toska E, Alig S, Durant M, de Stanchina E, ... ... Scheinberg DA, et al. Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma. Cancer Discovery. PMID 31915197 DOI: 10.1158/2159-8290.Cd-19-0116 |
0.631 |
|
| 2019 |
Oh CY, Klatt MG, Bourne C, Dao T, Dacek MM, Brea EJ, Mun SS, Chang AY, Korontsvit T, Scheinberg DA. ALK and RET inhibitors promote HLA class I antigen presentation and unmask new antigens within the tumor immunopeptidome. Cancer Immunology Research. PMID 31540894 DOI: 10.1158/2326-6066.Cir-19-0056 |
0.699 |
|
| 2019 |
Dao T, Mun SS, Scott AC, Jarvis CA, Korontsvit T, Yang Z, Liu L, Klatt MG, Guerreiro M, Selvakumar A, Brea EJ, Oh C, Liu C, Scheinberg DA. Depleting T regulatory cells by targeting intracellular Foxp3 with a TCR mimic antibody. Oncoimmunology. 8: 1570778. PMID 31143508 DOI: 10.1080/2162402X.2019.1570778 |
0.457 |
|
| 2019 |
Klatt MG, Gejman RS, Moon SS, Korontsvit TS, Dao T, Scheinberg DA. Abstract PR13: A new high-performance HLA ligand identification strategy enables prediction of T-cell tolerance to neoepitopes Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-Pr13 |
0.788 |
|
| 2019 |
Chandran S, Ma J, Klatt MG, Dündar F, Zumbo P, Femia MR, Betel D, Scheinberg DA, Baker BM, Klebanoff CA. Abstract CN01-03: T cell receptor gene therapy for a public neoantigen derived from mutated PIK3CA, a dominant driver oncogene in breast and endometrial cancers Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-Cn01-03 |
0.43 |
|
| 2018 |
Gejman RS, Chang AY, Jones HF, DiKun K, Hakimi AA, Schietinger A, Scheinberg DA. Rejection of immunogenic tumor clones is limited by clonal fraction. Elife. 7. PMID 30499773 DOI: 10.7554/Elife.41090 |
0.821 |
|
| 2018 |
Mondello P, Brea EJ, De Stanchina E, Toska E, Chang AY, Fennell M, Seshan V, Garippa R, Scheinberg DA, Baselga J, Wendel HG, Younes A. Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265 mutations. Jci Insight. 3. PMID 30429379 DOI: 10.1172/jci.insight.125568 |
0.543 |
|
| 2018 |
Maslak PG, Dao T, Bernal Y, Chanel SM, Zhang R, Frattini M, Rosenblat T, Jurcic JG, Brentjens RJ, Arcila ME, Rampal R, Park JH, Douer D, Katz L, Sarlis N, ... ... Scheinberg DA, et al. Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia. Blood Advances. 2: 224-234. PMID 29386195 DOI: 10.1182/Bloodadvances.2017014175 |
0.324 |
|
| 2018 |
Gejman RS, Chang AY, Jones HF, DiKun K, Hakimi AA, Schietinger A, Scheinberg DA. Author response: Rejection of immunogenic tumor clones is limited by clonal fraction Elife. DOI: 10.7554/Elife.41090.026 |
0.78 |
|
| 2018 |
Klatt MG, Mun SS, Socci ND, Korontsvit T, Dao T, Scheinberg DA. Epigenetic Drug Treatment Induces Presentation of New Class of Non-Exonic, Cryptic Neoantigens in Acute Myeloid Leukemia Cells Blood. 132: 2717-2717. DOI: 10.1182/Blood-2018-99-113691 |
0.435 |
|
| 2018 |
Klatt M, Gejman R, Mun SS, Dao T, Scheinberg D. Improved Sensitivity and Specificity for Mutated and Unmutated Class I HLA Ligand Identifications Lead to Better Immunotherapy Target Discovery Clinical Lymphoma Myeloma and Leukemia. 18: S297. DOI: 10.1016/J.Clml.2018.07.247 |
0.761 |
|
| 2017 |
Casey E, Bournazos S, Mo G, Mondello P, Tan KS, Ravetch JV, Scheinberg DA. A new mouse expressing human Fcγ receptors to better predict therapeutic efficacy of human anti-cancer antibodies. Leukemia. PMID 28924242 DOI: 10.1038/Leu.2017.293 |
0.343 |
|
| 2017 |
Chang AY, Dao T, Gejman RS, Jarvis CA, Scott A, Dubrovsky L, Mathias MD, Korontsvit T, Zakhaleva V, Curcio M, Hendrickson RC, Liu C, Scheinberg DA. A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens. The Journal of Clinical Investigation. 127: 3557. PMID 28862643 DOI: 10.1172/JCI96860 |
0.832 |
|
| 2017 |
Mathias MD, Sockolosky JT, Chang AY, Tan KS, Liu C, Garcia KC, Scheinberg DA. CD47 blockade enhances therapeutic activity of TCR mimic antibodies to ultra low density cancer epitopes. Leukemia. PMID 28745331 DOI: 10.1016/J.Clml.2016.07.013 |
0.625 |
|
| 2017 |
Chang AY, Dao T, Gejman RS, Jarvis CA, Scott A, Dubrovsky L, Mathias MD, Korontsvit T, Zakhaleva V, Curcio M, Hendrickson RC, Liu C, Scheinberg DA. A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens. The Journal of Clinical Investigation. PMID 28628042 DOI: 10.1172/Jci92335 |
0.841 |
|
| 2017 |
Mondello P, Brea EJ, De Stanchina E, Toska E, Chang AY, Fennell M, Seshan V, Garippa R, Scheinberg DA, Baselga J, Wendel HG, Younes A. Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265 mutations. Jci Insight. 2: e90196. PMID 28352655 DOI: 10.1172/Jci.Insight.90196 |
0.604 |
|
| 2017 |
Dao T, Korontsvit T, Zakhaleva V, Jarvis C, Mondello P, Oh C, Scheinberg DA. An immunogenic WT1-derived peptide that induces T cell response in the context of HLA-A*02:01 and HLA-A*24:02 molecules. Oncoimmunology. 6: e1252895. PMID 28344864 DOI: 10.1080/2162402X.2016.1252895 |
0.473 |
|
| 2017 |
Şenbabaoğlu Y, Gejman RS, Winer AG, Liu M, Van Allen EM, de Velasco G, Miao D, Ostrovnaya I, Drill E, Luna A, Weinhold N, Lee W, Manley BJ, Khalil DN, Kaffenberger SD, ... ... Scheinberg DA, et al. Erratum to: Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biology. 18: 46. PMID 28249590 DOI: 10.1186/S13059-017-1180-8 |
0.758 |
|
| 2017 |
Mondello P, Derenzini E, Asgari Z, Philip J, Brea EJ, Seshan V, Hendrickson RC, de Stanchina E, Scheinberg DA, Younes A. Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma. Oncotarget. PMID 28147336 DOI: 10.18632/oncotarget.14876 |
0.345 |
|
| 2017 |
Gejman RS, Dao T, Scheinberg DA. Identification of Cross-Reactive Targets of TCR-Based Therapeutic Agents within the Human Proteome Blood. 130: 3188-3188. DOI: 10.1182/Blood.V130.Suppl_1.3188.3188 |
0.819 |
|
| 2017 |
Scheinberg DA. Therapeutic TCR Mimic Monoclonal Antibodies to Intracellular Oncogenic Proteins Clinical Lymphoma Myeloma and Leukemia. 17: S214. DOI: 10.1016/J.Clml.2017.08.093 |
0.363 |
|
| 2016 |
Rafiq S, Purdon TJ, Daniyan AF, Koneru M, Dao T, Liu C, Scheinberg DA, Brentjens RJ. Optimized T-cell receptor-mimic (TCRm) chimeric antigen receptor T-cells directed towards the intracellular Wilms Tumor 1 antigen. Leukemia. PMID 27924074 DOI: 10.1038/Leu.2016.373 |
0.477 |
|
| 2016 |
Şenbabaoğlu Y, Gejman RS, Winer AG, Liu M, Van Allen EM, de Velasco G, Miao D, Ostrovnaya I, Drill E, Luna A, Weinhold N, Lee W, Manley BJ, Khalil DN, Kaffenberger SD, ... ... Scheinberg DA, et al. Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biology. 17: 231. PMID 27855702 DOI: 10.1186/S13059-016-1092-Z |
0.776 |
|
| 2016 |
Dubrovsky L, Brea EJ, Pankov D, Casey E, Dao T, Liu C, Scheinberg DA. Mechanisms of leukemia resistance to antibody dependent cellular cytotoxicity. Oncoimmunology. 5: e1211221. PMID 27757306 DOI: 10.1080/2162402X.2016.1211221 |
0.484 |
|
| 2016 |
Brea EJ, Oh CY, Manchado E, Budhu S, Gejman RS, Mo G, Mondello P, Han JE, Jarvis CA, Ulmert D, Xiang Q, Chang AY, Garippa RJ, Merghoub T, Wolchok JD, ... ... Scheinberg DA, et al. Kinase regulation of Human MHC Class I Molecule Expression on Cancer Cells. Cancer Immunology Research. PMID 27680026 DOI: 10.1158/2326-6066.Cir-16-0177 |
0.822 |
|
| 2016 |
Röhrig F, Vorlová S, Hoffmann H, Wartenberg M, Escorcia FE, Keller S, Tenspolde M, Weigand I, Gätzner S, Manova K, Penack O, Scheinberg DA, Rosenwald A, Ergün S, Granot Z, et al. VEGF-ablation therapy reduces drug delivery and therapeutic response in ECM-dense tumors. Oncogene. PMID 27270432 DOI: 10.1038/Onc.2016.182 |
0.685 |
|
| 2016 |
Behling K, DiGialleonardo V, Maguire WF, Heeb LE, Hassan IF, Veach DR, Keshari KR, Gutin PH, Scheinberg DA, McDevitt MR. Remodelling the vascular microenvironment of glioblastoma with alpha-particles. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 27261519 DOI: 10.2967/Jnumed.116.173559 |
0.349 |
|
| 2016 |
Behling K, Maguire WF, Puebla JC, Sprinkle SR, Ruggiero A, O'Donoghue J, Gutin PH, Scheinberg DA, McDevitt MR. Vascular targeted radioimmunotherapy for the treatment of glioblastoma. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 27127217 DOI: 10.2967/Jnumed.115.171371 |
0.345 |
|
| 2016 |
Y Chang A, Gejman R, J Brea E, Y Oh C, Mathias M, Pankov D, Casey E, Dao T, Scheinberg DA. Opportunities and challenges for TCR mimic antibodies in cancer therapy. Expert Opinion On Biological Therapy. PMID 27094818 DOI: 10.1080/14712598.2016.1176138 |
0.819 |
|
| 2016 |
Alidori S, Akhavein N, Thorek DL, Behling K, Romin Y, Queen D, Beattie BJ, Manova-Todorova K, Bergkvist M, Scheinberg DA, McDevitt MR. Targeted fibrillar nanocarbon RNAi treatment of acute kidney injury. Science Translational Medicine. 8: 331ra39. PMID 27009268 DOI: 10.1126/Scitranslmed.Aac9647 |
0.337 |
|
| 2016 |
Dubrovsky L, Dao T, Gejman RS, Brea EJ, Chang AY, Oh CY, Casey E, Pankov D, Scheinberg DA. T cell receptor mimic antibodies for cancer therapy. Oncoimmunology. 5: e1049803. PMID 26942058 DOI: 10.1080/2162402X.2015.1049803 |
0.833 |
|
| 2016 |
Zauderer MG, Dao T, Rusch VW, Ginsberg MS, Tsao AS, Panageas K, Stergiou AM, Scheinberg DA, Krug LM. Randomized phase II study of adjuvant WT1 vaccine (SLS-001) for malignant pleural mesothelioma (MPM) after multimodality therapy. Journal of Clinical Oncology. 34: 8519-8519. DOI: 10.1200/Jco.2016.34.15_Suppl.8519 |
0.333 |
|
| 2016 |
Maslak PG, Dao T, Bernal Y, Chanel SM, Zhang R, Frattini MG, Rosenblat TL, Jurcic JG, Rampal R, Park JH, Douer D, Katz L, Gutierrez AA, Tallman MS, Scheinberg DA. Phase II trial of WT1 analog peptide vaccine in adults with acute myeloid leukemia (AML) in first complete remission (CR). Journal of Clinical Oncology. 34: 7005-7005. DOI: 10.1200/Jco.2016.34.15_Suppl.7005 |
0.338 |
|
| 2016 |
Mathias MD, Sockolosky JT, Chang AY, Liu C, Garcia KC, Scheinberg DA. CD47 Blockade Enhances Therapeutic Activity of TCR Mimic Antibodies to Ultra-Low Density Cancer Epitopes through Cytokine Feed Forward Mechanisms Blood. 128: 4048-4048. DOI: 10.1182/Blood.V128.22.4048.4048 |
0.71 |
|
| 2016 |
Dao T, Pankov D, Scott A, Korontsvit T, Zakhaleva V, Guerrerio MDdM, Xu Y, Xiang J, Yan S, Veomett N, Dubrovsky L, Curcio M, Doubrovina E, Liu C, O'Reilly RJ, ... Scheinberg DA, et al. Abstract A055: Potent therapeutic and immunological effects of the first T-BiTE derived from a TCR-mimic antibody targeting intracellular oncoprotein WT1 Cancer Immunology Research. 4. DOI: 10.1158/2326-6074.Cricimteatiaacr15-A055 |
0.641 |
|
| 2016 |
Dao T, Jarvis C, Scott AC, Korontsvit T, Zakhaleva V, Pankov D, Guerrerio MDdM, Mathias M, Cheng N, Liu C, Scheinberg DA. Abstract A058: Selective targeting of T regulatory cells by a TCR-mimic monoclonal antibody specific for foxp3-derived epitopes Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-A058 |
0.493 |
|
| 2016 |
Brea EJ, Oh C, Manchado E, Gejman R, Mo G, Mondello P, Garippa R, Rosen N, Scheinberg DA. Abstract 4899: The regulation by kinases of the expression of human major histocompatibility class I molecules Cancer Research. 76: 4899-4899. DOI: 10.1158/1538-7445.Am2016-4899 |
0.775 |
|
| 2016 |
Dubrovsky L, Brea EJ, Pankov D, Casey E, Dao T, Liu C, Scheinberg DA. Mechanisms of leukemia resistance to antibody dependent cellular cytotoxicity Oncoimmunology. DOI: 10.1080/2162402X.2016.1211221 |
0.374 |
|
| 2016 |
Dubrovsky L, Dao T, Gejman RS, Brea EJ, Chang AY, Oh CY, Casey E, Pankov D, Scheinberg DA. T cell receptor mimic antibodies for cancer therapy Oncoimmunology. 5. DOI: 10.1080/2162402X.2015.1049803 |
0.806 |
|
| 2016 |
Rafiq S, Purdon T, Dao T, Liu C, Scheinberg D, Brentjens RJ. 393. Engineering Armored T Cell Receptor-Mimic (TCRm) Chimeric Antigen Receptor (CAR) T Cells Specific for the Intracellular Protein Wilms Tumor 1 (WT1) for Treatment of Hematologic and Solid Malignancies Molecular Therapy. 24: S156. DOI: 10.1016/S1525-0016(16)33202-6 |
0.455 |
|
| 2016 |
Mathias M, Sockolosky J, Chang A, Liu C, Garcia K, Scheinberg D. CD47 Blockade Enhances Therapeutic Activity of TCR Mimic Antibodies to Ultra-Low Density Cancer Epitopes Clinical Lymphoma Myeloma and Leukemia. 16: S8. DOI: 10.1016/j.clml.2016.07.013 |
0.585 |
|
| 2015 |
Ataie N, Xiang J, Cheng N, Brea EJ, Lu W, Scheinberg DA, Liu C, Ng HL. Structure of a TCR mimic antibody with target predicts pharmacogenetics. Journal of Molecular Biology. PMID 26688548 DOI: 10.1016/J.Jmb.2015.12.002 |
0.45 |
|
| 2015 |
Dao T, Pankov D, Scott A, Korontsvit T, Zakhaleva V, Xu Y, Xiang J, Yan S, de Morais Guerreiro MD, Veomett N, Dubrovsky L, Curcio M, Doubrovina E, Ponomarev V, Liu C, ... ... Scheinberg DA, et al. Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1. Nature Biotechnology. PMID 26389576 DOI: 10.1038/Nbt.3349 |
0.841 |
|
| 2015 |
Zanzonico P, Carrasquillo JA, Pandit-Taskar N, O'Donoghue JA, Humm JL, Smith-Jones P, Ruan S, Divgi C, Scott AM, Kemeny NE, Fong Y, Wong D, Scheinberg D, Ritter G, Jungbluth A, et al. PET-based compartmental modeling of (124)I-A33 antibody: quantitative characterization of patient-specific tumor targeting in colorectal cancer. European Journal of Nuclear Medicine and Molecular Imaging. 42: 1700-6. PMID 26194713 DOI: 10.1007/S00259-015-3061-2 |
0.411 |
|
| 2015 |
Matson ML, Villa CH, Ananta JS, Law JJ, Scheinberg DA, Wilson LJ. Encapsulation of α-Particle-Emitting 225Ac3+ Ions Within Carbon Nanotubes. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 56: 897-900. PMID 25931476 DOI: 10.2967/Jnumed.115.158311 |
0.654 |
|
| 2015 |
Jurcic JG, Ravandi F, Pagel JM, Park JH, Smith BD, Douer D, Levy MY, Estey E, Kantarjian HM, Earle D, Cicic D, Scheinberg DA. Phase I trial of {alpha}-particle therapy with actinium-225 (225Ac)-lintuzumab (anti-CD33) and low-dose cytarabine (LDAC) in older patients with untreated acute myeloid leukemia (AML. Journal of Clinical Oncology. 33: 7050-7050. DOI: 10.1200/Jco.2015.33.15_Suppl.7050 |
0.301 |
|
| 2015 |
Chang A, Dao T, Scott A, Dubrovsky L, Liu C, Scheinberg DA. A Therapeutic TCR Mimic Monoclonal Antibody for Intracellular PRAME Protein in Leukemias Blood. 126: 2527-2527. DOI: 10.1182/Blood.V126.23.2527.2527 |
0.698 |
|
| 2015 |
Koehne G, Kosuri S, Doubrovina E, Scheinberg D, Dao T, Scott A, O’Reilly R, Jungbluth A. Wilms’ tumor 1 protein is highly expressed on malignant plasma cells and provides a novel target for immunotherapeutic approaches Clinical Lymphoma Myeloma and Leukemia. 15: e283-e284. DOI: 10.1016/J.Clml.2015.07.582 |
0.356 |
|
| 2014 |
Villa JC, Chiu D, Brandes AH, Escorcia FE, Villa CH, Maguire WF, Hu CJ, de Stanchina E, Simon MC, Sisodia SS, Scheinberg DA, Li YM. Nontranscriptional role of Hif-1α in activation of γ-secretase and notch signaling in breast cancer. Cell Reports. 8: 1077-92. PMID 25131208 DOI: 10.1016/J.Celrep.2014.07.028 |
0.766 |
|
| 2014 |
Maguire WF, McDevitt MR, Smith-Jones PM, Scheinberg DA. Efficient 1-step radiolabeling of monoclonal antibodies to high specific activity with 225Ac for a-particle radioimmunotherapy of cancer Journal of Nuclear Medicine. 55: 1492-1498. PMID 24982438 DOI: 10.2967/Jnumed.114.138347 |
0.368 |
|
| 2014 |
Veomett N, Dao T, Liu H, Xiang J, Pankov D, Dubrovsky L, Whitten JA, Park SM, Korontsvit T, Zakhaleva V, Casey E, Curcio M, Kharas MG, O'Reilly RJ, Liu C, ... Scheinberg DA, et al. Therapeutic efficacy of an Fc-enhanced TCR-like antibody to the intracellular WT1 oncoprotein. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 4036-46. PMID 24850840 DOI: 10.1158/1078-0432.CCR-13-2756 |
0.837 |
|
| 2014 |
Dubrovsky L, Pankov D, Brea EJ, Dao T, Scott A, Yan S, O'Reilly RJ, Liu C, Scheinberg DA. A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias. Blood. 123: 3296-304. PMID 24723681 DOI: 10.1182/Blood-2014-01-549022 |
0.583 |
|
| 2014 |
Rafiq S, Dao T, Liu C, Scheinberg DA, Brentjens RJ. Engineered T Cell Receptor-Mimic Antibody, (TCRm) Chimeric Antigen Receptor (CAR) T Cells Against the Intracellular Protein Wilms Tumor-1 (WT1) for Treatment of Hematologic and Solid Cancers Blood. 124: 2155-2155. DOI: 10.1182/Blood.V124.21.2155.2155 |
0.468 |
|
| 2014 |
Henke E, Roehrig F, Hoffmann H, Escorcia F, Wartenberg M, Volova S, Gaetzner S, Rosenwald A, Erguen S, Scheinberg D, Granot Z. 266 Auxiliar treatment by targeting the extracellular matrix to improve drug delivery and therapeutic response European Journal of Cancer. 50: 89. DOI: 10.1016/S0959-8049(14)70392-2 |
0.656 |
|
| 2013 |
Mulvey JJ, Villa CH, McDevitt MR, Escorcia FE, Casey E, Scheinberg DA. Self-assembly of carbon nanotubes and antibodies on tumours for targeted amplified delivery Nature Nanotechnology. 8: 763-771. PMID 24077028 DOI: 10.1038/Nnano.2013.190 |
0.805 |
|
| 2013 |
Dao T, Liu C, Scheinberg DA. Approaching untargetable tumor-associated antigens with antibodies. Oncoimmunology. 2: e24678. PMID 24073363 DOI: 10.4161/Onci.24678 |
0.479 |
|
| 2013 |
Veomett N, Dao T, Scheinberg DA. Therapeutic antibodies to intracellular targets in cancer therapy. Expert Opinion On Biological Therapy. 13: 1485-8. PMID 23991764 DOI: 10.1517/14712598.2013.833602 |
0.822 |
|
| 2013 |
Scheinberg DA, McDevitt MR, Dao T, Mulvey JJ, Feinberg E, Alidori S. Carbon nanotubes as vaccine scaffolds Advanced Drug Delivery Reviews. 65: 2016-2022. PMID 23899863 DOI: 10.1016/J.Addr.2013.07.013 |
0.311 |
|
| 2013 |
Mallikaratchy P, Gardner J, Nordstrøm LU, Veomett NJ, McDevitt MR, Heaney ML, Scheinberg DA. A self-assembling short oligonucleotide duplex suitable for pretargeting. Nucleic Acid Therapeutics. 23: 289-99. PMID 23848521 DOI: 10.1089/Nat.2013.0425 |
0.787 |
|
| 2013 |
Scheinberg DA, Dao T, Liu C. Reaching un-drugable intracellular targets with the long arm of antibodies. Oncotarget. 4: 647-8. PMID 23800785 DOI: 10.18632/Oncotarget.1039 |
0.533 |
|
| 2013 |
Dao T, Yan S, Veomett N, Pankov D, Zhou L, Korontsvit T, Scott A, Whitten J, Maslak P, Casey E, Tan T, Liu H, Zakhaleva V, Curcio M, Doubrovina E, ... ... Scheinberg DA, et al. Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. Science Translational Medicine. 5: 176ra33. PMID 23486779 DOI: 10.1126/Scitranslmed.3005661 |
0.835 |
|
| 2013 |
Dubrovsky L, Brea EJ, Veomett NJ, Dao T, Yan S, Liu C, Scheinberg DA. Therapeutic superiority of a TCR-like antibody to an intracellular WT1 oncogene peptide compared with the tyrosine kinase inhibitor imatinib in a mouse model of Philadelphia chromosome positive (Ph+) ALL. Journal of Clinical Oncology. 31: 3047-3047. DOI: 10.1200/Jco.2013.31.15_Suppl.3047 |
0.821 |
|
| 2013 |
Dubrovsky L, Brea E, Pankov D, Veomett N, Dao T, Yan S, Liu C, Scheinberg DA. Therapeutic Efficacy and Cure Of Sensitive and T315I Pan-Resistant Human Ph+ Leukemia In Mice Using a TCR-Like Antibody To WT1/HLA-A0201 Alone, Or In Combination With Tyrosine Kinase Inhibitors Blood. 122: 855-855. DOI: 10.1182/Blood.V122.21.855.855 |
0.812 |
|
| 2013 |
Pankov D, Dao T, Wang Y, Scott A, Korontsvit T, Zakhaleva V, Veomett N, Curcio M, Doubrovina E, O'Reilly RJ, Liu C, Scheinberg DA. A Bi-Specific T Cell Engaging Monoclonal Antibody (mAb) Derived From a TCR-Like Mab Specific For WT1/HLA-A0201 (ESK-BiTE) Shows a Potent Activity Against Human AML and Ph+ ALL In Mouse Models Blood. 122: 2521-2521. DOI: 10.1182/Blood.V122.21.2521.2521 |
0.828 |
|
| 2013 |
Jurcic JG, Ravandi F, Pagel JM, Park JH, Douer D, Estey EH, Kantarjian HM, Cicic D, Scheinberg DA. Phase I Trial Of The Targeted Alpha-Particle Nano-Generator Actinium-225 (225Ac)-Lintuzumab (Anti-CD33) In Combination With Low-Dose Cytarabine (LDAC) For Older Patients With Untreated Acute Myeloid Leukemia (AML) Blood. 122: 1460-1460. DOI: 10.1182/Blood.V122.21.1460.1460 |
0.302 |
|
| 2013 |
Jurcic J, Rosenblat T, McDevitt M, Pandit-Taskar N, Carrasquillo J, Chanel S, Zikaras K, Frattini M, Maslak P, Cicic D, Larson S, Scheinberg D. Targeted Alpha-particle Nano-generator Actinium-225 (225Ac)-lintuzumab (anti-CD33) in Acute Myeloid Leukemia (AML) Clinical Lymphoma Myeloma and Leukemia. 13: S379-S380. DOI: 10.1016/J.Clml.2013.07.088 |
0.301 |
|
| 2012 |
Haro KJ, Sheth A, Scheinberg DA. Dysregulation of IRP1-mediated iron metabolism causes gamma ray-specific radioresistance in leukemia cells. Plos One. 7: e48841. PMID 23155415 DOI: 10.1371/Journal.Pone.0048841 |
0.775 |
|
| 2012 |
Haro KJ, Scott AC, Scheinberg DA. Mechanisms of resistance to high and low linear energy transfer radiation in myeloid leukemia cells. Blood. 120: 2087-97. PMID 22829630 DOI: 10.1182/Blood-2012-01-404509 |
0.774 |
|
| 2012 |
Chau DM, Crump CJ, Villa JC, Scheinberg DA, Li YM. Familial Alzheimer disease presenilin-1 mutations alter the active site conformation of γ-secretase. The Journal of Biological Chemistry. 287: 17288-96. PMID 22461631 DOI: 10.1074/Jbc.M111.300483 |
0.556 |
|
| 2012 |
Tseng HM, Shum D, Bhinder B, Escobar S, Veomett NJ, Tomkinson AE, Gin DY, Djaballah H, Scheinberg DA. A high-throughput scintillation proximity-based assay for human DNA ligase IV. Assay and Drug Development Technologies. 10: 235-49. PMID 22192310 DOI: 10.1089/Adt.2011.0404 |
0.776 |
|
| 2012 |
Veomett N, Dao T, Pankov D, Yan S, O'Reilly RJ, Liu C, Scheinberg DA. Native and Fc Enhanced Therapeutic Human Monoclonal Antibodies Targeting the Intracellular WT1 Oncogene Product in Leukemia. Blood. 120: 2599-2599. DOI: 10.1182/Blood.V120.21.2599.2599 |
0.832 |
|
| 2012 |
Gardner JR, Devlin S, Knapp K, Bauli F, Lamanna N, Frattini MG, Brentjens RJ, Maslak PG, Jurcic JG, Weiss M, Scheinberg DA, Heaney M. Aerobic Glycolysis Predicts Outcome in Early Chronic Lymphocytic Leukemia. Blood. 120: 2482-2482. DOI: 10.1182/Blood.V120.21.2482.2482 |
0.309 |
|
| 2011 |
Scheinberg DA, McDevitt MR. Actinium-225 in targeted alpha-particle therapeutic applications. Current Radiopharmaceuticals. 4: 306-20. PMID 22202153 DOI: 10.2174/1874471011104040306 |
0.316 |
|
| 2011 |
Brentjens RJ, Rivière I, Park JH, Davila ML, Wang X, Stefanski J, Taylor C, Yeh R, Bartido S, Borquez-Ojeda O, Olszewska M, Bernal Y, Pegram H, Przybylowski M, Hollyman D, ... ... Scheinberg D, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 118: 4817-28. PMID 21849486 DOI: 10.1182/Blood-2011-04-348540 |
0.418 |
|
| 2011 |
Carrasquillo JA, Pandit-Taskar N, O'Donoghue JA, Humm JL, Zanzonico P, Smith-Jones PM, Divgi CR, Pryma DA, Ruan S, Kemeny NE, Fong Y, Wong D, Jaggi JS, Scheinberg DA, Gonen M, et al. (124)I-huA33 antibody PET of colorectal cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 52: 1173-80. PMID 21764796 DOI: 10.2967/Jnumed.110.086165 |
0.342 |
|
| 2011 |
Antczak C, Shum D, Bassit B, Frattini MG, Li Y, de Stanchina E, Scheinberg DA, Djaballah H. Identification of benzofuran-4,5-diones as novel and selective non-hydroxamic acid, non-peptidomimetic based inhibitors of human peptide deformylase. Bioorganic & Medicinal Chemistry Letters. 21: 4528-32. PMID 21719286 DOI: 10.1016/J.Bmcl.2011.05.129 |
0.353 |
|
| 2011 |
Villa CH, Dao T, Ahearn I, Fehrenbacher N, Casey E, Rey DA, Korontsvit T, Zakhaleva V, Batt CA, Philips MR, Scheinberg DA. Single-walled carbon nanotubes deliver peptide antigen into dendritic cells and enhance IgG responses to tumor-associated antigens. Acs Nano. 5: 5300-11. PMID 21682329 DOI: 10.1021/Nn200182X |
0.736 |
|
| 2011 |
Seideman JH, Stancevic B, Rotolo JA, McDevitt MR, Howell RW, Kolesnick RN, Scheinberg DA. Alpha particles induce apoptosis through the sphingomyelin pathway. Radiation Research. 176: 434-46. PMID 21631289 DOI: 10.1667/Rr2472.1 |
0.787 |
|
| 2011 |
Grimm J, Scheinberg DA. Will nanotechnology influence targeted cancer therapy? Seminars in Radiation Oncology. 21: 80-7. PMID 21356476 DOI: 10.1016/J.Semradonc.2010.10.003 |
0.343 |
|
| 2011 |
Mallikaratchy PR, Ruggiero A, Gardner JR, Kuryavyi V, Maguire WF, Heaney ML, McDevitt MR, Patel DJ, Scheinberg DA. A multivalent DNA aptamer specific for the B-cell receptor on human lymphoma and leukemia. Nucleic Acids Research. 39: 2458-69. PMID 21030439 DOI: 10.1093/Nar/Gkq996 |
0.406 |
|
| 2011 |
Jurcic JG, Rosenblat TL, McDevitt MR, Pandit-Taskar N, Carrasquillo JA, Chanel SM, Zikaras K, Frattini MG, Maslak PG, Cicic D, Larson SM, Scheinberg DA. Phase I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225 (225Ac)-Lintuzumab (Anti-CD33; HuM195) in Acute Myeloid Leukemia (AML) Blood. 118: 768-768. DOI: 10.1182/Blood.V118.21.768.768 |
0.323 |
|
| 2011 |
Scheinberg DA, Dao T, Yan S, Zhou L, Korontsvit T, Zakhaleva V, Curcio M, Liu C. A Cytotoxic Human Monoclonal Antibody Recognizing Cell Surface WT1 Peptide/HLA-A2 Complexes Blood. 118: 1677-1677. DOI: 10.1182/Blood.V118.21.1677.1677 |
0.49 |
|
| 2011 |
Scheinberg DA, Villa CH, Escorcia F, Mcdevitt MR. Carbon Nanotubes Drug Delivery in Oncology: From Basic Research to Cancer Therapy. 2: 1163-1185. DOI: 10.1002/9783527634057.ch36 |
0.732 |
|
| 2010 |
Escorcia FE, Henke E, McDevitt MR, Villa CH, Smith-Jones P, Blasberg RG, Benezra R, Scheinberg DA. Selective killing of tumor neovasculature paradoxically improves chemotherapy delivery to tumors. Cancer Research. 70: 9277-86. PMID 21045141 DOI: 10.1158/0008-5472.Can-10-2029 |
0.797 |
|
| 2010 |
Ruggiero A, Villa CH, Holland JP, Sprinkle SR, May C, Lewis JS, Scheinberg DA, McDevitt MR. Imaging and treating tumor vasculature with targeted radiolabeled carbon nanotubes. International Journal of Nanomedicine. 5: 783-802. PMID 21042424 DOI: 10.2147/Ijn.S13300 |
0.71 |
|
| 2010 |
Rosenblat TL, McDevitt MR, Mulford DA, Pandit-Taskar N, Divgi CR, Panageas KS, Heaney ML, Chanel S, Morgenstern A, Sgouros G, Larson SM, Scheinberg DA, Jurcic JG. Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 5303-11. PMID 20858843 DOI: 10.1158/1078-0432.Ccr-10-0382 |
0.377 |
|
| 2010 |
Seideman JH, Shum D, Djaballah H, Scheinberg DA. A high-throughput screen for alpha particle radiation protectants. Assay and Drug Development Technologies. 8: 602-14. PMID 20658946 DOI: 10.1089/Adt.2010.0291 |
0.767 |
|
| 2010 |
Ruggiero A, Villa CH, Bander E, Rey DA, Bergkvist M, Batt CA, Manova-Todorova K, Deen WM, Scheinberg DA, McDevitt MR. Paradoxical glomerular filtration of carbon nanotubes. Proceedings of the National Academy of Sciences of the United States of America. 107: 12369-74. PMID 20566862 DOI: 10.1073/Pnas.0913667107 |
0.663 |
|
| 2010 |
O'Reilly RJ, Dao T, Koehne G, Scheinberg D, Doubrovina E. Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation. Seminars in Immunology. 22: 162-72. PMID 20537908 DOI: 10.1016/J.Smim.2010.02.003 |
0.551 |
|
| 2010 |
Krug LM, Dao T, Brown AB, Maslak P, Travis W, Bekele S, Korontsvit T, Zakhaleva V, Wolchok J, Yuan J, Li H, Tyson L, Scheinberg DA. WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer. Cancer Immunology, Immunotherapy : Cii. 59: 1467-79. PMID 20532500 DOI: 10.1007/S00262-010-0871-8 |
0.378 |
|
| 2010 |
Penack O, Henke E, Suh D, King CG, Smith OM, Na IK, Holland AM, Ghosh A, Lu SX, Jenq RR, Liu C, Murphy GF, Lu TT, May C, Scheinberg DA, et al. Inhibition of neovascularization to simultaneously ameliorate graft-vs-host disease and decrease tumor growth. Journal of the National Cancer Institute. 102: 894-908. PMID 20463307 DOI: 10.1093/Jnci/Djq172 |
0.364 |
|
| 2010 |
Maslak PG, Dao T, Krug LM, Chanel S, Korontsvit T, Zakhaleva V, Zhang R, Wolchok JD, Yuan J, Pinilla-Ibarz J, Berman E, Weiss M, Jurcic J, Frattini MG, Scheinberg DA. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood. 116: 171-9. PMID 20400682 DOI: 10.1182/Blood-2009-10-250993 |
0.368 |
|
| 2010 |
Scheinberg DA, Villa CH, Escorcia FE, McDevitt MR. Conscripts of the infinite armada: systemic cancer therapy using nanomaterials. Nature Reviews. Clinical Oncology. 7: 266-76. PMID 20351700 DOI: 10.1038/Nrclinonc.2010.38 |
0.794 |
|
| 2010 |
Sofou S, Enmon R, Palm S, Kappel B, Zanzonico P, McDevitt MR, Scheinberg DA, Sgouros G. Large anti-HER2/neu liposomes for potential targeted intraperitoneal therapy of micrometastatic cancer. Journal of Liposome Research. 20: 330-40. PMID 20070139 DOI: 10.3109/08982100903544185 |
0.734 |
|
| 2009 |
Dao T, Korontsvit T, Zakhaleva V, Haro K, Packin J, Scheinberg DA. Identification of a human cyclin D1-derived peptide that induces human cytotoxic CD4 T cells. Plos One. 4: e6730. PMID 19707583 DOI: 10.1371/Journal.Pone.0006730 |
0.81 |
|
| 2009 |
Jain N, Reuben JM, Kantarjian H, Li C, Gao H, Lee BN, Cohen EN, Ebarb T, Scheinberg DA, Cortes J. Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial. Cancer. 115: 3924-34. PMID 19536894 DOI: 10.1002/Cncr.24468 |
0.339 |
|
| 2009 |
Escobar-Alvarez S, Goldgur Y, Yang G, Ouerfelli O, Li Y, Scheinberg DA. Structure and activity of human mitochondrial peptide deformylase, a novel cancer target. Journal of Molecular Biology. 387: 1211-28. PMID 19236878 DOI: 10.1016/J.Jmb.2009.02.032 |
0.312 |
|
| 2009 |
Seideman JH, Scheinberg DA. Multi-Drug Resistance Phenotype in Myeloid Leukemia Cells Confers Radiation Resistance Via DNA Damage Sensor Uncoupling. Blood. 114: 4243-4243. DOI: 10.1182/Blood.V114.22.4243.4243 |
0.783 |
|
| 2009 |
Escorcia FE, Henke E, McDevitt MR, Villa C, Smith-Jones P, Blasberg R, Benezra R, Scheinberg DA. Vascular Endothelial-Cadherin Targeted Alpha-Particle Mediated Vascular Killing and Remodeling Augments Subsequent Chemotherapeutic Efficacy. Blood. 114: 3054-3054. DOI: 10.1182/Blood.V114.22.3054.3054 |
0.802 |
|
| 2009 |
Mallikaratchy P, Ruggiero A, Maguire W, Piersanti K, Gardner J, Villa C, Escorcia F, Palomba ML, Heaney M, McDevitt MR, Scheinberg DA. Multivalent DNA Aptamer-Based Therapeutic Agents for Lymphoma and Leukemia. Blood. 114: 2711-2711. DOI: 10.1182/Blood.V114.22.2711.2711 |
0.811 |
|
| 2008 |
Villa CH, McDevitt MR, Escorcia FE, Rey DA, Bergkvist M, Batt CA, Scheinberg DA. Synthesis and biodistribution of oligonucleotide-functionalized, tumor-targetable carbon nanotubes. Nano Letters. 8: 4221-8. PMID 19367842 DOI: 10.1021/Nl801878D |
0.785 |
|
| 2008 |
Gómez-Nuñez M, Haro KJ, Dao T, Chau D, Won A, Escobar-Alvarez S, Zakhaleva V, Korontsvit T, Gin DY, Scheinberg DA. Non-natural and photo-reactive amino acids as biochemical probes of immune function. Plos One. 3: e3938. PMID 19079589 DOI: 10.1371/Journal.Pone.0003938 |
0.801 |
|
| 2008 |
Dudkin VY, Miller JS, Dudkina AS, Antczak C, Scheinberg DA, Danishefsky SJ. Toward a prostate specific antigen-based prostate cancer diagnostic assay: preparation of keyhole limpet hemocyanin-conjugated normal and transformed prostate specific antigen fragments. Journal of the American Chemical Society. 130: 13598-607. PMID 18798614 DOI: 10.1021/Ja8028137 |
0.311 |
|
| 2008 |
Dao T, Scheinberg DA. Peptide vaccines for myeloid leukaemias. Best Practice & Research. Clinical Haematology. 21: 391-404. PMID 18790445 DOI: 10.1016/J.Beha.2008.05.001 |
0.323 |
|
| 2008 |
Miederer M, Scheinberg DA, McDevitt MR. Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications. Advanced Drug Delivery Reviews. 60: 1371-82. PMID 18514364 DOI: 10.1016/J.Addr.2008.04.009 |
0.322 |
|
| 2008 |
Penack O, Henke E, Suh D, King C, Smith MO, Na I, Holland A, Ghosh A, Lu SX, Jenq R, Liu C, Murphy GF, Lu T, May C, Scheinberg DA, et al. Depletion of Vascular Endothelial Progenitor Cells Inhibits Inflammation Blood. 112: 694-694. DOI: 10.1182/Blood.V112.11.694.694 |
0.379 |
|
| 2008 |
Rosenblat T, McDevitt MR, Mulford DA, Pandit-Taskar N, Weiss MA, Heaney ML, Chanel S, Morgenstern A, Larson SM, Scheinberg DA, Jurcic JG. Sequential Cytarabine and Alpha-Particle Immunotherapy with Bismuth-213 (213Bi)-Labeled-HuM195 (Lintuzumab) for Acute Myeloid Leukemia (AML) Blood. 112: 2983-2983. DOI: 10.1182/Blood.V112.11.2983.2983 |
0.321 |
|
| 2007 |
Escorcia FE, McDevitt MR, Villa CH, Scheinberg DA. Targeted nanomaterials for radiotherapy. Nanomedicine (London, England). 2: 805-15. PMID 18095847 DOI: 10.2217/17435889.2.6.805 |
0.813 |
|
| 2007 |
Sofou S, Kappel BJ, Jaggi JS, McDevitt MR, Scheinberg DA, Sgouros G. Enhanced retention of the α-particle-emitting daughters of actinium-225 by liposome carriers Bioconjugate Chemistry. 18: 2061-2067. PMID 17935286 DOI: 10.1021/Bc070075T |
0.734 |
|
| 2007 |
McDevitt MR, Chattopadhyay D, Jaggi JS, Finn RD, Zanzonico PB, Villa C, Rey D, Mendenhall J, Batt CA, Njardarson JT, Scheinberg DA. PET imaging of soluble yttrium-86-labeled carbon nanotubes in mice. Plos One. 2: e907. PMID 17878942 DOI: 10.1371/Journal.Pone.0000907 |
0.655 |
|
| 2007 |
Jaggi JS, Carrasquillo JA, Seshan SV, Zanzonico P, Henke E, Nagel A, Schwartz J, Beattie B, Kappel BJ, Chattopadhyay D, Xiao J, Sgouros G, Larson SM, Scheinberg DA. Improved tumor imaging and therapy via i.v. IgG-mediated time-sequential modulation of neonatal Fc receptor. The Journal of Clinical Investigation. 117: 2422-30. PMID 17717602 DOI: 10.1172/Jci32226 |
0.76 |
|
| 2007 |
May RJ, Dao T, Pinilla-Ibarz J, Korontsvit T, Zakhaleva V, Zhang RH, Maslak P, Scheinberg DA. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 4547-55. PMID 17671141 DOI: 10.1158/1078-0432.Ccr-07-0708 |
0.412 |
|
| 2007 |
McDevitt MR, Chattopadhyay D, Kappel BJ, Jaggi JS, Schiffman SR, Antczak C, Njardarson JT, Brentjens R, Scheinberg DA. Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubes. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 48: 1180-9. PMID 17607040 DOI: 10.2967/Jnumed.106.039131 |
0.763 |
|
| 2007 |
Nolan DJ, Ciarrocchi A, Mellick AS, Jaggi JS, Bambino K, Gupta S, Heikamp E, McDevitt MR, Scheinberg DA, Benezra R, Mittal V. Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization. Genes & Development. 21: 1546-58. PMID 17575055 DOI: 10.1101/Gad.436307 |
0.353 |
|
| 2007 |
Antczak C, Shum D, Escobar S, Bassit B, Kim E, Seshan VE, Wu N, Yang G, Ouerfelli O, Li YM, Scheinberg DA, Djaballah H. High-throughput identification of inhibitors of human mitochondrial peptide deformylase. Journal of Biomolecular Screening. 12: 521-35. PMID 17435169 DOI: 10.1177/1087057107300463 |
0.336 |
|
| 2007 |
Singh Jaggi J, Henke E, Seshan SV, Kappel BJ, Chattopadhyay D, May C, McDevitt MR, Nolan D, Mittal V, Benezra R, Scheinberg DA. Selective alpha-particle mediated depletion of tumor vasculature with vascular normalization Plos One. 2. PMID 17342201 DOI: 10.1371/Journal.Pone.0000267 |
0.726 |
|
| 2007 |
Maslak PG, Jurcic JG, Scheinberg DA. Monoclonal antibody therapy of APL Current Topics in Microbiology and Immunology. 313: 205-219. PMID 17217045 DOI: 10.1007/978-3-540-34594-7_11 |
0.357 |
|
| 2007 |
Ise T, Nagata S, Kreitman RJ, Wilson WH, Wayne AS, Stetler-Stevenson M, Bishop MR, Scheinberg DA, Rassenti L, Kipps TJ, Kyle RA, Jelinek DF, Pastan I. Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma. Leukemia. 21: 169-74. PMID 17051241 DOI: 10.1038/Sj.Leu.2404445 |
0.317 |
|
| 2007 |
Rosenblat TL, McDevitt MR, Pandit-Taskar N, Carrasquillo JA, Chanel S, Frattini MG, Larson SM, Scheinberg DA, Jurcic JG. Phase I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225 (225Ac)-HuM195 (Anti-CD33) in Acute Myeloid Leukemia (AML). Blood. 110: 910-910. DOI: 10.1182/Blood.V110.11.910.910 |
0.347 |
|
| 2007 |
Maslak PG, Krug L, Chanel S, Dao T, James L, Tyson L, Bekele S, Scheinberg DA. Pilot Study of a Wilms Tumor Protein (WT1) Heteroclitic Peptide Vaccine in Patients with Myeloid and Thoracic Neoplasms. Blood. 110: 903-903. DOI: 10.1182/Blood.V110.11.903.903 |
0.396 |
|
| 2007 |
Haro KJ, Gomez-Nunez M, Dao T, Chau D, Won A, Escobar-Alvarez S, Zakhaleva V, Korontsvit T, Gin D, Scheinberg DA. Photo-Reactive and Non-Natural Amino Acid Epitopes of Human WT1 Enhance Immunogenicity and Allow Kinetic Study of Antigen Processing. Blood. 110: 2311-2311. DOI: 10.1182/Blood.V110.11.2311.2311 |
0.811 |
|
| 2007 |
Jaggi JS, Carrasquillo JA, Seshan SV, Zanzonico P, Henke E, Nagel A, Schwartz J, Beattie B, Kappel BJ, Chattopadhyay D, Xiao J, Sgouros G, Larson SM, Scheinberg DA. Erratum: Improved tumor imaging and therapy via i.v. IgG-mediated time-sequential modulation of neonatal Fc receptor (Journal of Clinical Investigation (2007) 117, (2422-2430) DOI: 10.1172/JCI32226)) Journal of Clinical Investigation. 117. DOI: 10.1172/Jci32226C1 |
0.72 |
|
| 2006 |
Antczak C, Jaggi JS, LeFave CV, Curcio MJ, McDevitt MR, Scheinberg DA. Influence of the linker on the biodistribution and catabolism of actinium-225 self-immolative tumor-targeted isotope generators. Bioconjugate Chemistry. 17: 1551-60. PMID 17105236 DOI: 10.1021/Bc060156+ |
0.384 |
|
| 2006 |
Pinilla-Ibarz J, May RJ, Korontsvit T, Gomez M, Kappel B, Zakhaleva V, Zhang RH, Scheinberg DA. Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein Leukemia. 20: 2025-2033. PMID 16990779 DOI: 10.1038/Sj.Leu.2404380 |
0.772 |
|
| 2006 |
Scheinberg DA, Jurcic JG, Maslak P. Antibody-drug conjugates in acute myeloid leukemia. Nature Clinical Practice. Oncology. 3: 238-9. PMID 16682998 DOI: 10.1038/Ncponc0478 |
0.308 |
|
| 2006 |
Gomez-Nunez M, Pinilla-Ibarz J, Dao T, May RJ, Pao M, Jaggi JS, Scheinberg DA. Peptide binding motif predictive algorithms correspond with experimental binding of leukemia vaccine candidate peptides to HLA-A*0201 molecules Leukemia Research. 30: 1293-1298. PMID 16533527 DOI: 10.1016/J.Leukres.2006.02.010 |
0.368 |
|
| 2006 |
Bonavia AS, McDevitt MR, Curcio MJ, Scheinberg DA. Immunoreactivity assay for alpha-particle emitting monoclonal antibody constructs. Applied Radiation and Isotopes : Including Data, Instrumentation and Methods For Use in Agriculture, Industry and Medicine. 64: 470-4. PMID 16352433 DOI: 10.1016/J.Apradiso.2005.11.004 |
0.353 |
|
| 2006 |
Kappel BJ, Pinilla-Ibarz J, Kochman AA, Eng JM, Hubbard VM, Leiner I, Pamer EG, Heller G, van den Brink MR, Scheinberg DA. Remodeling specific immunity by use of MHC tetramers: demonstration in a graft-versus-host disease model. Blood. 107: 2045-51. PMID 16269613 DOI: 10.1182/Blood-2005-07-2828 |
0.762 |
|
| 2006 |
May RJ, Pinilla J, Korontsvit T, Zakhaleva V, Zhang RH, Dao T, Maslak P, Scheinberg DA. CD4+ Peptide Epitopes from the WT1 Oncoprotein Stimulate CD4+ and CD8+ T Cells That Recognize and Kill Leukemia and Solid Tumor Cells. Blood. 108: 3706-3706. DOI: 10.1182/Blood.V108.11.3706.3706 |
0.4 |
|
| 2006 |
Cortes J, Reuben JM, Scheinberg D, Lee B, Gao H, Li C, Mazanet R, Jones D, Kantarjian H. A Pilot Phase II Trial of a Synthetic Tumor-Specific Breakpoint Peptide Vaccine in Patients with Chronic Myeloid Leukemia (CML) and Minimal Residual Disease. Blood. 108: 2196-2196. DOI: 10.1182/Blood.V108.11.2196.2196 |
0.346 |
|
| 2005 |
Dao T, Gomez-Nunez M, Antczak C, Kappel B, Jaggi JS, Korontsvit T, Zakhaleva V, Scheinberg DA. Natural killer cells license dendritic cell cross-presentation of B lymphoma cell--associated antigens. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 8763-72. PMID 16361564 DOI: 10.1158/1078-0432.Ccr-05-0975 |
0.769 |
|
| 2005 |
Kotzerke J, Bunjes D, Scheinberg DA. Radioimmunoconjugates in acute leukemia treatment: The future is radiant Bone Marrow Transplantation. 36: 1021-1026. PMID 16247432 DOI: 10.1038/Sj.Bmt.1705182 |
0.345 |
|
| 2005 |
Jaggi JS, Seshan SV, McDevitt MR, LaPerle K, Sgouros G, Scheinberg DA. Renal tubulointerstitial changes after internal irradiation with alpha-particle-emitting actinium daughters. Journal of the American Society of Nephrology : Jasn. 16: 2677-89. PMID 15987754 DOI: 10.1681/Asn.2004110945 |
0.3 |
|
| 2005 |
Feldman EJ, Brandwein J, Stone R, Kalaycio M, Moore J, O'Connor J, Wedel N, Roboz GJ, Miller C, Chopra R, Jurcic JC, Brown R, Ehmann WC, Schulman P, Frankel SR, ... ... Scheinberg D, et al. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 4110-6. PMID 15961759 DOI: 10.1200/Jco.2005.09.133 |
0.313 |
|
| 2005 |
Jaggi JS, Kappel BJ, McDevitt MR, Sgouros G, Flombaum CD, Cabassa C, Scheinberg DA. Efforts to control the errant products of a targeted in vivo generator. Cancer Research. 65: 4888-95. PMID 15930310 DOI: 10.1158/0008-5472.Can-04-3096 |
0.717 |
|
| 2005 |
Gale RP, Horowitz MM, Talpaz M, Scheinberg DA, Molldrem J, Li Z, Baccarani M, Goldman JM, Tura S. Immune therapy of chronic myelogenous leukemia. Leukemia Research. 29: 583-6. PMID 15755511 DOI: 10.1016/J.Leukres.2004.11.005 |
0.393 |
|
| 2005 |
Gomez-Nunez M, Pinilla-Ibarz J, Dao T, Korontsvit T, Zakhaleva V, May RJ, Scheinberg DA. Reliability of Computer Algorithm-Based Binding Predictions for the Identification of Leukemia Antigens. Blood. 106: 4483-4483. DOI: 10.1182/Blood.V106.11.4483.4483 |
0.389 |
|
| 2005 |
May RJ, Korontsvit T, Zakhaleva V, Gomez M, Dao T, Scheinberg DA. Generation of Specific Human CD8+ T Cell Responses to the Myeloproliferative Disorder Associated V617F Mutated JAK2 Kinase by Use of Analog Peptide Vaccine Candidates. Blood. 106: 3512-3512. DOI: 10.1182/Blood.V106.11.3512.3512 |
0.393 |
|
| 2005 |
Gomez-Nunez M, Pinilla-Ibarz J, Dao T, Zakhaleva V, Korontsvit T, May RJ, Scheinberg DA. Immunogenicity of a BCR-ABL e1a2 p190 Translocation in a Balb/c Mouse Model. Blood. 106: 2868-2868. DOI: 10.1182/Blood.V106.11.2868.2868 |
0.374 |
|
| 2005 |
Gupta S, Weiss MA, Jurcic JG, Chanel S, Wilson B, Biederman E, Berman E, Scheinberg DA, Maslak PG. Induction with Combined Modality Therapy Followed by Immunomodulated Post Remission Therapy for Newly Diagnosed Acute Myeloid Leukemia (AML). Blood. 106: 2802-2802. DOI: 10.1182/Blood.V106.11.2802.2802 |
0.3 |
|
| 2005 |
Kappel BJ, Pinilla-Ibarz J, Kochman AA, Eng JM, Hubbard VM, Leiner IM, Pamer EG, van den Brink MR, Scheinberg DA. Remodeling Specific Immunity by Use of MHC-Tetramers Distinguishes Graft-Versus-Tumor Activity from Graft-Versus-Host-Disease. Blood. 106: 1300-1300. DOI: 10.1182/Blood.V106.11.1300.1300 |
0.767 |
|
| 2005 |
Finn R, McDevitt M, Sheh Y, Lom C, Qiao J, Cai S, Burnazi E, Nacca A, Pillarsetty N, Jaggi J, Scheinberg D. Cyclotron production of cesium radionuclides as analogues for francium-221 biodistribution Nuclear Instruments and Methods in Physics Research Section B: Beam Interactions With Materials and Atoms. 241: 649-651. DOI: 10.1016/J.Nimb.2005.07.162 |
0.423 |
|
| 2004 |
Caligiuri MA, Velardi A, Scheinberg DA, Borrello IM. Immunotherapeutic approaches for hematologic malignancies. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 337-53. PMID 15561691 DOI: 10.1182/Asheducation-2004.1.337 |
0.398 |
|
| 2004 |
Miederer M, McDevitt MR, Borchardt P, Bergman I, Kramer K, Cheung NK, Scheinberg DA. Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 6985-92. PMID 15501978 DOI: 10.1158/1078-0432.Ccr-04-0859 |
0.35 |
|
| 2004 |
Lee MD, She Y, Soskis MJ, Borella CP, Gardner JR, Hayes PA, Dy BM, Heaney ML, Philips MR, Bornmann WG, Sirotnak FM, Scheinberg DA. Human mitochondrial peptide deformylase, a new anticancer target of actinonin-based antibiotics. The Journal of Clinical Investigation. 114: 1107-16. PMID 15489958 DOI: 10.1172/Jci22269 |
0.593 |
|
| 2004 |
Ballangrud AM, Yang WH, Palm S, Enmon R, Borchardt PE, Pellegrini VA, McDevitt MR, Scheinberg DA, Sgouros G. Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 4489-97. PMID 15240541 DOI: 10.1158/1078-0432.Ccr-03-0800 |
0.306 |
|
| 2004 |
Yuan RR, Wong P, McDevitt MR, Doubrovina E, Leiner I, Bornmann W, O'reilly R, Pamer EG, Scheinberg DA. Targeted deletion of T-cell clones using alpha-emitting suicide MHC tetramers. Blood. 104: 2397-402. PMID 15217835 DOI: 10.1182/Blood-2004-01-0324 |
0.559 |
|
| 2004 |
Moldenhauer A, Frank RC, Pinilla-Ibarz J, Holland G, Boccuni P, Scheinberg DA, Salama A, Seeger K, Moore MA, Nimer SD. Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with AML1-containing fusion proteins. Journal of Leukocyte Biology. 76: 623-33. PMID 15197237 DOI: 10.1189/Jlb.1103581 |
0.395 |
|
| 2004 |
Cathcart K, Pinilla-Ibarz J, Korontsvit T, Schwartz J, Zakhaleva V, Papadopoulos EB, Scheinberg DA. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood. 103: 1037-42. PMID 14504104 DOI: 10.1182/Blood-2003-03-0954 |
0.338 |
|
| 2004 |
Pinilla J, May R, Gomez M, Korontsvit T, Barry K, Zakhaleva V, Dao T, Scheinberg DA. Generating Human Immune Responses to Mutations in Bcr-Abl Kinase Selected by Imatinib. Blood. 104: 4689-4689. DOI: 10.1182/Blood.V104.11.4689.4689 |
0.37 |
|
| 2004 |
Mulford DA, Pandit-Taskar N, McDevitt MR, Finn RD, Weiss MA, Apostolidis C, Morgenstern A, Divgi CR, Larson SM, Scheinberg DA, Jurcic JG. Sequential Therapy with Cytarabine and Bismuth-213 (213Bi)-Labeled-HuM195 (Anti-CD33) for Acute Myeloid Leukemia (AML). Blood. 104: 1790-1790. DOI: 10.1182/Blood.V104.11.1790.1790 |
0.302 |
|
| 2004 |
Kappel B, Eng J, Pinilla-Ibarz J, van den Brink M, Scheinberg D. Selective depletion of T cell clones responsible for GVHD in a murine model Biology of Blood and Marrow Transplantation. 10: 20-21. DOI: 10.1016/J.Bbmt.2003.12.076 |
0.732 |
|
| 2003 |
Lee MD, Antczak C, Li Y, Sirotnak FM, Bornmann WG, Scheinberg DA. A new human peptide deformylase inhibitable by actinonin. Biochemical and Biophysical Research Communications. 312: 309-15. PMID 14637138 DOI: 10.1016/J.Bbrc.2003.10.123 |
0.57 |
|
| 2003 |
Burke JM, Caron PC, Papadopoulos EB, Divgi CR, Sgouros G, Panageas KS, Finn RD, Larson SM, O'Reilly RJ, Scheinberg DA, Jurcic JG. Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias Bone Marrow Transplantation. 32: 549-556. PMID 12953125 DOI: 10.1038/Sj.Bmt.1704201 |
0.501 |
|
| 2003 |
Duzkale H, Pagliaro LC, Rosenblum MG, Varan A, Liu B, Reuben J, Wierda WG, Korbling M, McMannis JD, Glassman AB, Scheinberg DA, Freireich EJ. Bone marrow purging studies in acute myelogenous leukemia using the recombinant anti-CD33 immunotoxin HuM195/rGel. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 9: 364-72. PMID 12813444 DOI: 10.1016/S1083-8791(03)00129-0 |
0.373 |
|
| 2003 |
Feldman E, Kalaycio M, Weiner G, Frankel S, Schulman P, Schwartzberg L, Jurcic J, Velez-Garcia E, Seiter K, Scheinberg D, Levitt D, Wedel N. Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195. Leukemia. 17: 314-8. PMID 12592328 DOI: 10.1038/Sj.Leu.2402803 |
0.322 |
|
| 2003 |
Schwartz J, Pinilla-Ibarz J, Yuan RR, Scheinberg DA. Novel targeted and immunotherapeutic strategies in chronic myeloid leukemia. Seminars in Hematology. 40: 87-96. PMID 12563615 DOI: 10.1053/shem.2003.50007 |
0.327 |
|
| 2003 |
Scheinberg DA. Additional alpha applications Blood. 101: 4651-4651. DOI: 10.1182/Blood-2003-04-1079 |
0.318 |
|
| 2003 |
Schwartz J, Pinilla-Ibarz J, Yuan RR, Scheinberg DA. Novel targeted and immunotherapeutic strategies in chronic myeloid leukemia Seminars in Hematology. 40: 87-96. DOI: 10.1016/S0037-1963(03)70046-8 |
0.435 |
|
| 2002 |
McDevitt MR, Ma D, Simon J, Frank RK, Scheinberg DA. Design and synthesis of 225Ac radioimmunopharmaceuticals. Applied Radiation and Isotopes : Including Data, Instrumentation and Methods For Use in Agriculture, Industry and Medicine. 57: 841-7. PMID 12406626 DOI: 10.1016/S0969-8043(02)00167-7 |
0.341 |
|
| 2002 |
Roberts WK, Livingston PO, Agus DB, Pinilla-Ibarz J, Zelenetz A, Scheinberg DA. Vaccination with CD20 peptides induces a biologically active, specific immune response in mice. Blood. 99: 3748-55. PMID 11986232 DOI: 10.1182/Blood.V99.10.3748 |
0.387 |
|
| 2002 |
Burke JM, Jurcic JG, Scheinberg DA. Radioimmunotherapy for acute leukemia. Cancer Control : Journal of the Moffitt Cancer Center. 9: 106-13. PMID 11965231 DOI: 10.1177/107327480200900203 |
0.384 |
|
| 2002 |
Ma D, McDevitt MR, Barendswaard E, Lai L, Curcio MJ, Pellegrini V, Brechbiel MW, Scheinberg DA. Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies Leukemia. 16: 60-66. PMID 11840264 DOI: 10.1038/Sj.Leu.2402320 |
0.369 |
|
| 2002 |
McDevitt MR, Ma D, Lai LT, Simon J, Borchardt P, Frank RK, Wu K, Pellegrini V, Curcio MJ, Miederer M, Bander NH, Scheinberg DA. Tumor therapy with targeted atomic nanogenerators. Science (New York, N.Y.). 294: 1537-40. PMID 11711678 DOI: 10.1126/Science.1064126 |
0.41 |
|
| 2002 |
Jurcic JG, Larson SM, Sgouros G, McDevitt MR, Finn RD, Divgi CR, Ballangrud ÅM, Hamacher KA, Ma D, Humm JL, Brechbiel MW, Molinet R, Scheinberg DA. Targeted α particle immunotherapy for myeloid leukemia Blood. 100: 1233-1239. DOI: 10.1182/Blood.V100.4.1233.H81602001233_1233_1239 |
0.358 |
|
| 2001 |
Ma D, McDevitt MR, Finn RD, Scheinberg DA. Rapid preparation of short-lived alpha particle emitting radioimmunopharmaceuticals Applied Radiation and Isotopes. 55: 463-470. PMID 11545498 DOI: 10.1016/S0969-8043(01)00048-3 |
0.305 |
|
| 2001 |
Ballangrud AM, Yang WH, Charlton DE, McDevitt MR, Hamacher KA, Panageas KS, Ma D, Bander NH, Scheinberg DA, Sgouros G. Response of LNCaP spheroids after treatment with an α-particle emitter (213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591) Cancer Research. 61: 2008-2014. PMID 11280760 |
0.306 |
|
| 2001 |
Maslak P, Scheinberg D. Targeted therapies for the myeloid leukaemias. Expert Opinion On Investigational Drugs. 9: 1197-205. PMID 11060736 DOI: 10.1517/13543784.9.6.1197 |
0.36 |
|
| 2001 |
Scheinberg DA. Finally, able to present ABL Blood. 98: 2885-2885. DOI: 10.1182/Blood.V98.10.2885 |
0.326 |
|
| 2000 |
Frankel AE, Sievers EL, Scheinberg DA. Cell surface receptor-targeted therapy of acute myeloid leukemia: A review Cancer Biotherapy and Radiopharmaceuticals. 15: 459-476. PMID 11155818 DOI: 10.1089/Cbr.2000.15.459 |
0.464 |
|
| 2000 |
Pinilla-Ibarz J, Cathcart K, Scheinberg DA. CML vaccines as a paradigm of the specific immunotherapy of cancer Blood Reviews. 14: 111-120. PMID 11012250 DOI: 10.1054/Blre.2000.0127 |
0.455 |
|
| 2000 |
Jurcic JG, Cathcart K, Pinilla-Ibarz J, Scheinberg DA. Advances in immunotherapy of hematologic malignancies: Cellular and humoral approaches Current Opinion in Hematology. 7: 247-254. PMID 10882181 DOI: 10.1097/00062752-200007000-00008 |
0.485 |
|
| 2000 |
Houghton AN, Scheinberg DA. Monoclonal antibody therapies - A 'constant' threat to cancer Nature Medicine. 6: 373-374. PMID 10742135 DOI: 10.1038/74621 |
0.362 |
|
| 2000 |
Pinilla-Ibarz J, Cathcart K, Korontsvit T, Soignet S, Bocchia M, Caggiano J, Lai L, Jimenez J, Kolitz J, Scheinberg DA. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses Blood. 95: 1781-1787. DOI: 10.1182/Blood.V95.5.1781.005K46_1781_1787 |
0.38 |
|
| 1999 |
Jurcic JG, Scheinberg DA. Radionuclides as conditioning before stem cell transplantation Current Opinion in Hematology. 6: 371-376. PMID 10546789 DOI: 10.1097/00062752-199911000-00003 |
0.348 |
|
| 1999 |
Hom JS, Goldberg I, Mathis J, Pan YX, Brooks AI, Ryan-Moro J, Scheinberg DA, Pasternak GW. [(125)I]orphanin FQ/nociceptin binding in Raji cells. Synapse (New York, N.Y.). 34: 187-91. PMID 10523756 DOI: 10.1002/(Sici)1098-2396(19991201)34:3<187::Aid-Syn3>3.0.Co;2-A |
0.31 |
|
| 1999 |
Weisburg JH, Roepe PD, Dzekunov S, Scheinberg DA. Intracellular ph and multidrug resistance regulate complement-mediated cytotoxicity of nucleated human cells Journal of Biological Chemistry. 274: 10877-10888. PMID 10196165 DOI: 10.1074/Jbc.274.16.10877 |
0.335 |
|
| 1998 |
Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, Corso D, DeBlasio A, Gabrilove J, Scheinberg DA, Pandolfi PP, Warrell RP. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide New England Journal of Medicine. 339: 1341-1348. PMID 9801394 DOI: 10.1056/Nejm199811053391901 |
0.327 |
|
| 1998 |
Wang ZG, Rivi R, Delva L, König A, Scheinberg DA, Gambacorti-Passerini C, Gabrilove JL, Warrell RP, Pandolfi PP. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARα independent manner Blood. 92: 1497-1504. PMID 9716575 DOI: 10.1182/Blood.V92.5.1497.417K41_1497_1504 |
0.337 |
|
| 1997 |
Caron PC, Scheinberg DA. The biological therapy of acute and chronic leukemia Cancer Investigation. 15: 342-352. PMID 9246157 DOI: 10.3109/07357909709039738 |
0.397 |
|
| 1997 |
Larson SM, Divgi CR, Scott A, Sgouros G, Graham MC, Kostakoglu L, Scheinberg D, Cheung NK, Schlom J, Finn RD. Current status of radioimmunotherapy. Nuclear Medicine and Biology. 21: 785-92. PMID 9241655 DOI: 10.1016/0969-8051(94)90050-7 |
0.367 |
|
| 1996 |
O'Boyle KP, Freeman K, Kalisiak A, Agregado A, Scheinberg DA. Patterns of ganglioside expression in B cell neoplasms Leukemia and Lymphoma. 21: 255-266. PMID 8726407 DOI: 10.3109/10428199209067607 |
0.336 |
|
| 1996 |
Weisburg JH, Curcio M, Caron PC, Raghu G, Mechetner EB, Roepe PD, Scheinberg DA. The multidrug resistance phenotype confers immunological resistance Journal of Experimental Medicine. 183: 2699-2704. PMID 8676093 DOI: 10.1084/Jem.183.6.2699 |
0.339 |
|
| 1996 |
Xu Y, Xu Q, Rosenblum MG, Scheinberg DA. Antileukemic activity of recombinant humanized M195-gelonin immunotoxin in nude mice Leukemia. 10: 321-326. PMID 8637241 |
0.313 |
|
| 1996 |
Scheinberg DA. Passive and active specific immunotherapy of myeloid leukemias Experimental Hematology. 24: 1121. |
0.369 |
|
| 1995 |
Nikula TK, Curcio MJ, Brechbiel MW, Gansow OA, Finn RD, Scheinberg DA. A rapid, single vessel method for preparation of clinical grade ligand conjugated monoclonal antibodies. Nuclear Medicine and Biology. 22: 387-90. PMID 7627155 DOI: 10.1016/0969-8051(94)00126-5 |
0.302 |
|
| 1995 |
Nikula TK, Bocchia M, Curcio MJ, Sgouros G, Ma Y, Finn RD, Scheinberg DA. Impact of the high tyrosine fraction in complementarity determining regions: measured and predicted effects of radioiodination on IgG immunoreactivity Molecular Immunology. 32: 865-872. PMID 7565813 DOI: 10.1016/0161-5890(95)00052-G |
0.337 |
|
| 1995 |
Jurcic JG, Caron PC, Scheinberg DA. Monoclonal antibody therapy of leukemia and lymphoma Advances in Pharmacology (San Diego, Calif.). 33: 287-314. PMID 7495673 DOI: 10.1016/S1054-3589(08)60672-9 |
0.438 |
|
| 1994 |
Caron PC, Scheinberg DA. Immunotherapy for acute leukemias Current Opinion in Oncology. 6: 14-22. PMID 8204688 DOI: 10.1097/00001622-199401000-00003 |
0.384 |
|
| 1994 |
McGraw KJ, Rosenblum MG, Cheung L, Scheinberg DA. Characterization of murine and humanized anti-CD33, gelonin immunotoxins reactive against myeloid leukemias. Cancer Immunology, Immunotherapy : Cii. 39: 367-74. PMID 8001024 DOI: 10.1007/Bf01534423 |
0.399 |
|
| 1994 |
Jurcic JG, Scheinberg DA. Recent developments in the radioimmunotherapy of cancer Current Opinion in Immunology. 6: 715-721. PMID 7826526 DOI: 10.1016/0952-7915(94)90074-4 |
0.42 |
|
| 1993 |
Czuczman MS, Garin-Chesa P, Lemoli RM, Scheinberg DA. IgM monoclonal antibody JD118 recognizes an inducible antigen target for human-complement-mediated cytotoxicity against neoplastic B cells Cancer Immunology Immunotherapy. 36: 387-396. PMID 8500111 DOI: 10.1007/Bf01742255 |
0.459 |
|
| 1993 |
Czuczman MS, Straus DJ, Divgi CR, Graham M, Garin-Chesa P, Finn R, Myers J, Old LJ, Larson SM, Scheinberg DA. Phase I dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-hodgkin's lymphoma Journal of Clinical Oncology. 11: 2021-2029. PMID 8410126 DOI: 10.1200/Jco.1993.11.10.2021 |
0.323 |
|
| 1993 |
Man Sung Co, Scheinberg DA, Avdalovic NM, Mcgraw K, Vasquez M, Caron PC, Queen C. Genetically engineered deglycosylation of the variable domain increases the affinity of an anti-CD33 monoclonal antibody Molecular Immunology. 30: 1361-1367. PMID 8232322 DOI: 10.1016/0161-5890(93)90097-U |
0.345 |
|
| 1993 |
Caron PC, Scheinberg DA. Anti-CD33 monoclonal antibody m195 for the therapy of myeloid leukemia Leukemia and Lymphoma. 11: 1-6. PMID 8124221 DOI: 10.3109/10428199309064254 |
0.391 |
|
| 1993 |
Sgouros G, Scheinberg DA. Treatment of leukemia with radiolabeled monoclonal antibodies Cancer Treatment and Research. 68: 23-64. PMID 8105852 DOI: 10.1007/978-1-4615-3076-3_3 |
0.437 |
|
| 1993 |
Scheinberg DA. Monoclonal antibodies in the treatment of myelogenous leukemias Cancer Treatment and Research. 64: 213-232. PMID 7680876 DOI: 10.1007/978-1-4615-3086-2_11 |
0.44 |
|
| 1992 |
Caron PC, Laird W, Co MS, Avdalovic NM, Queen C, Scheinberg DA. Engineered humanized dimeric forms of IgG are more effective antibodies Journal of Experimental Medicine. 176: 1191-1195. PMID 1402660 DOI: 10.1084/Jem.176.4.1191 |
0.389 |
|
| 1991 |
Lemoli RM, Gasparetto C, Scheinberg DA, Moore MAS, Clarkson BD, Gulati SC. Autologous bone marrow transplantation in acute myelogenous leukemia: In vitro treatment with myeloid-specific monoclonal antibodies and drugs in combination Blood. 77: 1829-1836. PMID 2015406 DOI: 10.1182/Blood.V77.8.1829.Bloodjournal7781829 |
0.359 |
|
| 1991 |
Scheinberg DA, Lovett D, Divgi CR, Graham MC, Berman E, Pentlow K, Feirt N, Finn RD, Clarkson BD, Gee TS, Larson SM, Oettgen HF. A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: Specific bone marrow targeting and internalization of radionuclide Journal of Clinical Oncology. 9: 478-490. PMID 1999719 DOI: 10.1200/Jco.1991.9.3.478 |
0.333 |
|
| 1991 |
Oosterwijk E, Kalisiak A, Wakka JC, Scheinberg DA, Old LJ. Monoclonal antibodies against Galα1-4Galβ1-4Glc (P(k), CD77) produced with a synthetic glycoconjugate as immunogen: Reactivity with carbohydrates, with fresh frozen human tissues and hematopoietic tumors International Journal of Cancer. 48: 848-854. PMID 1860732 DOI: 10.1002/Ijc.2910480610 |
0.371 |
|
| 1991 |
Kalisiak A, Oosterwijk E, Minniti JG, Old LJ, Scheinberg DA. A monoclonal antibody for terminal β-galactose. Use in analysis of glycosphingolipids Glycoconjugate Journal. 8: 55-62. PMID 1726670 DOI: 10.1007/Bf00731643 |
0.339 |
|
| 1991 |
Scheinberg DA, Bull MK, Yang SY, Class KA, Minniti JG. Inhibition of cell proliferation with an HLA-A-specific monoclonal antibody. Tissue Antigens. 38: 213-23. PMID 1723543 DOI: 10.1111/J.1399-0039.1991.Tb01900.X |
0.38 |
|
| 1991 |
Scheinberg DA. Current applications of monoclonal antibodies for the therapy of hematopoietic cancers Current Opinion in Immunology. 3: 679-684. PMID 1661602 DOI: 10.1016/0952-7915(91)90096-J |
0.413 |
|
| 1991 |
Chapman PB, Scheinberg DA, DiMaggio JJ, Houghton AN. Unconjugated monoclonal antibodies as anticancer agents Immunology and Allergy Clinics of North America. 11: 257-275. |
0.308 |
|
| 1990 |
Scheinberg DA, Straus DJ, Yeh SD, Divgi C, Garin-Chesa P, Graham M, Pentlow K, Coit D, Oettgen HF, Old LJ. A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma: Effects of tumor burden and antigen expression Journal of Clinical Oncology. 8: 792-803. PMID 2332769 DOI: 10.1200/Jco.1990.8.5.792 |
0.374 |
|
| 1990 |
Yuasa H, Scheinberg DA, Houghton AN. Gangliosides of T lymphocytes: Evidence for a role in T-cell activation Tissue Antigens. 36: 47-56. PMID 2270542 DOI: 10.1111/J.1399-0039.1990.Tb01799.X |
0.309 |
|
| 1990 |
Shimazaki C, Fried J, Perez AG, Scheinberg DA, Atzpodien J, Wang CY, Wisniewolski R, Clarkson BD. Immunophenotypic analysis of lymphocytes and myeloma cells in patients with multiple myeloma. Acta Haematologica. 83: 123-9. PMID 2109450 DOI: 10.1159/000205187 |
0.398 |
|
| 1989 |
Tanimoto M, Scheinberg DA, Cordon-Cardo C, Huie D, Clarkson BD, Old LJ. Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195 Leukemia. 3: 339-348. PMID 2716349 |
0.325 |
|
| 1988 |
Shimazaki C, Wisniewski D, Scheinberg DA, Atzpodien J, Strife A, Gulati S, Fried J, Wisniewolski R, Wang CY, Clarkson BD. Elimination of myeloma cells from bone marrow by using monoclonal antibodies and magnetic immunobeads Blood. 72: 1248-1254. PMID 3167207 DOI: 10.1182/Blood.V72.4.1248.Bloodjournal7241248 |
0.396 |
|
| 1988 |
Minamoto GY, Gold JW, Scheinberg DA, Hardy WD, Chein N, Zuckerman E, Reich L, Dietz K, Gee T, Hoffer J. Infection with human T-cell leukemia virus type I in patients with leukemia. The New England Journal of Medicine. 318: 219-22. PMID 2892132 DOI: 10.1056/Nejm198801283180405 |
0.3 |
|
| 1983 |
Scheinberg DA, Pan XQ, Wilsnack R, Strand M. Rapid screening of monoclonal antibodies: New 'microstick' radioimmunoassay Journal of Immunological Methods. 58: 285-292. PMID 6833770 DOI: 10.1016/0022-1759(83)90356-3 |
0.679 |
|
| 1983 |
Krakow JS, Scheinberg DA, Strand M. A microradioiodination method for detection of nanogram amounts of proteins resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis Journal of Virological Methods. 7: 273-278. PMID 6677646 DOI: 10.1016/0166-0934(83)90079-4 |
0.625 |
|
| 1983 |
Scheinberg DA, Strand M. Kinetic and Catabolic Considerations of Monoclonal Antibody Targeting in Erythroleukemic Mice Cancer Research. 43: 265-272. PMID 6571707 |
0.32 |
|
| 1982 |
Scheinberg DA, Strand M, Gansow OA. Tumor imaging with radioactive metal chelates conjugated to monoclonal antibodies. Science (New York, N.Y.). 215: 1511-3. PMID 7199757 DOI: 10.1126/Science.7199757 |
0.376 |
|
| 1981 |
Scheinberg DA, Strand M. 55,000-Dalton, retrovirus-associated, cell membrane glycoprotein: Purification and quantitative measurements of expression in viruses, cells, and tissues Molecular and Cellular Biology. 1: 144-152. PMID 6965096 DOI: 10.1128/Mcb.1.2.144 |
0.679 |
|
| 1981 |
Scheinberg DA, Strand M. A brain membrane protein similar to the rat src gene product Proceedings of the National Academy of Sciences of the United States of America. 78: 55-59. PMID 6264448 DOI: 10.1073/Pnas.78.1.55 |
0.647 |
|
| 1980 |
Scheinberg DA, Strand M. Transformation-related proteins associated with Kirsten sarcoma virus Virology. 106: 335-348. PMID 6254255 DOI: 10.1016/0042-6822(80)90257-3 |
0.658 |
|
| 1979 |
Myerson D, Scheinberg D, Klement V, Strand M, August JT. Characterization of a defective pseudotype particle of Kirsten sarcoma virus. Virology. 95: 536-49. PMID 223292 DOI: 10.1016/0042-6822(79)90507-5 |
0.652 |
|
| Show low-probability matches. |